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Abstract  We studied the serum levels of IL-2, IFN-γ and TNF in different clinical forms of
Chagas' disease and in patients clinically compensated and decompensated. Cytokines
measured in 91 patients with the chronic form of the disease did not differ from those of 13
normal individuals, suggesting the absence of activation of the TH1 pattern of lymphocyte
response. There were no statistical differences among the 17 patients in the indeterminate form
of the disease, the patients presenting either early (n = 4) or well-developed signs of
cardiomyopathy (n = 62), the digestive (n = 4) or the mixed (n = 4) forms of the disease. Serum
TNF was undetectable and IFN-γ levels did not differ between clinical forms and severities of
Chagas’ disease. However, we found IL-2 higher levels in the 25 non-controlled patients than in
the 66 controlled individuals (p < 0,001). We suggest that IL-2 dosage may be useful as an
indicator of the need for more aggressive procedures.
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ARTIGO
Resumo  Estudamos os níveis séricos da IL-2, IFN-γ e do TNF-α de portadores da doença de
Chagas em suas diferentes formas clínicas, compensados e descompensados. As citocinas
medidas nos 91 pacientes com a forma crônica da doença não diferiram dos níveis de 13
indivíduos controle. Não houve diferença estatística entre os 17 portadores da forma
indeterminada da doença e os portadores de cardiopatia insipiente (n = 4), de cardiopatia bem
estabelecida (n = 62), da forma digestiva (n = 4) ou da forma mista (n = 4) da doença. Os
níveis séricos de TNF foram indetectáveis e IFN-γ não diferiu nas diferentes formas clínicas ou
com a severidade da doença. No entanto, encontramos níveis mais elevados de IL-2 nos 25
pacientes não-contrololados do que nos 66 pacientes bem compensados (p < 0,001).
Sugerimos que a dosagem de IL-2 possa servir como indicadora da necessidade de
terapêuticas mais agressivas nestes pacientes.
Palavras-chaves: Miocardiopatia. Forma clínica. Severidade. Citocinas. Doença de Chagas.
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Citocinas séricas na forma crônica da doenca de Chagas
Chagas' disease is estimated to affect 18
million people in Brazil6. The disease is one of
the most important causes of morbidity and
mortality in a broad area ranging from Argentina
to the South of the United States16 28 .
C h a r a c t e r i s t i c a l l y, after a self-limited acute
phase, the immune response controls parasitism
yet fails to completely eradicate the protozoan
parasite. It is interesting that in the chronic phase,
Chagas' disease becomes clinically manifested
in less than 60% of the infected individuals who
develop the characteristic cardiac and/or digestive
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manifestations of the disease17. The heart is the
organ most frequently affected, followed by the
autonomic nervous system, the lesion of which
leads to the digestive form of the disease17. The
pathogeny of the disease is still unclear, but
three main mechanisms have been proposed for
it: the neurogenic, the microvascular and the
immunological-autoimmunity theories12 22. The
few existing studies of the acute human infection
demonstrate an abnormal immunological
response to the parasite25 26. Immunologic findings
in the chronic phase are more difficult to interpret,
particularly considering the different clinical
forms of the disease. Aseries of manifestations of
immune-suppression have been demonstrated
in experimental animals and in human, but the
mechanism by which they develop remains
obscure13 20 21 26. Depressed responses were
reported in patients with either the cardiac or the
digestive form of Chagas' disease although
parasite antigen-specific and/or mitogen-induced
PBMC proliferative responses were reported to
be normal4. Normal levels of NK cell activity and
normal IL-2 activated cytotoxicity (LAK) were
shown in both symptomatic and non-symptomatic
cardiac patients23. On the other hand, NK cell
activity was found to be enhanced by in vitro
exposure of PBMC to T. cruzi antigen in all but
symptomatic patients3. Increased HLA-DR
expression by peripheral blood T-cells and a
higher frequency of CD28T cells have been
described in both symptomatic and indeterminate
phase patients but neither IL-2 or IL-4 message
in PBMC nor serum IL-2r levels were found to
be augmented4 7 8 9.
Because of their well-known actions in the
inflammatory response, some investigators have
attempted to relate cytokines levels to the
severity of diseases10 21 24 27. We and others
also demonstrated that chagasic patients with
d i fferent clinical forms of the disease have
peripheral blood mononuclear cells, which
respond to T. cru z i antigen with a cytotoxic
response that is selectively up regulated by IL-
122 3. However, we found no difference in the
increment caused by cytokine treatment among
the different forms of Chagas' disease2.
In the present study, we have examined
some important cytokines levels in patients of
chronic Chagas' disease with different clinical
forms and severity.
MATERIALAND METHODS
Controls. The Medical Ethics Committee of
the Hospital das Clínicas (FCM/UNICAMP)
granted permission to study 20 healthy medical
students who volunteered to provide normal
parameters for the cytokine assays. After careful
clinical examination, a blood sample was obtained
from each subject for serum IL-2, IFN γ a n d
T N Fα determinations. All individuals were
observed for a period of four to eight weeks and
when they were suspected of any immune or
inflammatory disease, their data were eliminated
from analysis of the results. At the end of the
observation period, only six males and seven
females were selected (median age 24 years,
range 21 to 27 years) and denoted group N.
Patients. Ninety one Chagas' disease patients
were sequentially selected among the individuals
who routinely attend the outpatient clinic. After a
careful clinical observation and a review of
each patient medical records, the subjects were
classif ied as (-) when they had few or no
symptoms, i.e., when they did not present
manifestations of Chagas' disease and/or of any
concomitant pathology, and as (+) when they
were symptomatic or in an advanced stage of
heart disease (functional type IV by the criteria
of the Committee of the American Cardiology
Association41. Again we discarded all data from
patients suspected of any other concurrent active
immune or inflammatory disease.
According to their clinical manifestation of
the disease, the patients were divided into:
. G roup I (indeterminate fo r m ) : s e v e n t e e n
patients (8 M, 9 F) aged 21 to 71 years (X = 48
± 15 years) non-symptomatic, with no cardiac
or visceral manifestations, although they had
serologic tests confirming Chagas' disease. Eight
of these patients had other diagnoses that
included asthma (one case), arterial hypertension
(four cases), coronary artery disease (two
cases) and peptic ulcer (one case), but no one
presented clinical manifestations during the
period of observation of this study.
. Group II (early cardiac form): four patients
(2M, 2F) aged 45 to 58 years (X = 54 ± 10
years) showed abnormalities in the ECG but
had normal cardiac function. Although the four
had other concomitant diagnosis, including
chronic obstructive pulmonary disease and
coronary artery disease (two cases each), no
one presented clinical manifestations during
the observation period.
Revista da Sociedade Brasileira de Medicina Tropical 32:285-289, mai-jun, 1999.
287
. G roup III (card i o myo p a t hy ) : sixty-two patients
(20 M, 42F) aged 34 to 71 years (X = 55 ± 8.5
years) with Chagas' cardiac disease. T h e s e
patients had been using amiodarone to control
their arrhythmia at the dose of Mo = 400mg/day
for about 4 years (Mo = 4 years). At the time of
blood collection, 24 of these patients presented
decompensated heart disease with clear clinical
manifestations (22 patients were functional
type III, and two patients were classified as
functional type IV).
. Group IV (digestive form): four patients (1 M,
3F) aged 38 to 62 years (X = 51 ± 13 years) with
megaesophagus or megacolon confirmed by
radiological examination but no sign of cardiac
disease. One of these individuals also had a
well-controlled hypertension.
. Group V (mixed form): four patients (4 F) aged
37 to 67 years (X = 54 ± 7 years) with the
combined manifestations of groups III + IV. No
patient was using amiodarone. One of these
individuals presented signs of non-compensated
heart disease at the time of blood collection.
Methods.  Blood sampl ing took p lace
between 9:00 and 13:00h. The samples were
immediately processed and stored at -20oC until
assayed. IL-2, γ-IFN and TNF-α were measured
by solid-phase enzyme immunoassays employing
the mult iple antibody sandwich principle
(Intertest-2 Human Interleukin-2, Intertest-γ
Human IFN-γ and Predicta Tumor Necrosis
Factor-α ELISA kits), obtained from Genzyme
Diagnostics, Cambridge, MA, USA. IL-2 kit had
a detection limit of 100pg/ml. IFN-γ kit also had
a detection limit of 100pg/ml. TNF-α detection
limit was 10pg/ml. 
Statistical analysis. The results are expressed
as the mean ± standard error. Since the data did
not show a normal distribution, they were analyzed
by the Kruskal-Wallis (H statistic) test, the χ2 test
or Wilcoxon's rank sum test (Z statistic), as
appropriate. Statistical analysis that did not reach
a level of significance of p < 0.05 were considered
as non-significant (NS). For statistical purposes,
undetectable cytokine levels were assigned an
arbitrary level corresponding to the least
detectable value of the method.
RESULTS
Normal individuals did not di f fer from
C h a g a s ’ disease patients in terms of age or gender
(χ2 = NS). There was also no difference among
the patients grouped according to their clinical
form (I to V) (χ2 = NS). The results of both normal
individuals and Chagas' disease patients are
shown in Table 1. IL-2 levels ranged from 200 to
5120pg/dL, γ-IFN ranged from 42 to 190 pg/dL,
and TNF was undetectable in all individuals. T h e r e
was no significant difference in serum cytokine
levels between normal individuals and chagasic
patients. Analysis of the 91 patients as a whole
showed no correlation among IL2, TNF and IFN-γ
levels.  Considering the forms of c l in ical
Table 1 - Serum thyroid hormones and cytokines levels of normal individuals (group N) and Chagas’ disease patients
divided into groups I (indeterminate form), II (early cardiac form), III (cardiomyopathy), IV (digestive form) and V (mixed
form). Values are reported as Mean ± SEM.
Group TSH T4l T3 T4 Tg IL-2 TNF IFN-γ
mU/L ng/dL ng/dL µg/dL ng/dL pg/dL pg/dL pg/dL
N 1.34 ± 0.37 1.04 ± 0.52 117.8 ±  7.8 8.9 ±  1.7 12.2  ±  3.3 1671.57 ± 445.23 ND 112.35 ± 14.54
I 4.68 ± 1.13 1.19 ± 0.28 128.66 ± 31.20 6.5 ± 1.5 12.05 ± 2.92 1476.47 ± 358.10 ND 122.31 ± 29.66
II 5.40 ± 2.70 1.53 ± 0.76 181.96 ± 90.98 10.6 ± 5.3 10.25 ± 5.12 1285.00 ± 642.50 ND 118.75 ± 94.37
III 5.05 ± 0.70 1.28 ± 0.17 116.17 ± 16.26 8.5 ± 1.1 80.88 ± 11.32 1057.07 ± 148.04 ND 122.62 ± 17.17
IV 1.01 ± 0.50 1.28 ± 0.64 NP NP 46.13 ± 23.06 1000.00 ± 500.00 ND 125.75 ± 62.87
V 16.53 ± 8.26 1.15 ± 0.50 91.66 ± 45.83 8.5 ± 4.2 224 ± 112.00 725.00 ± 362.50 ND 100.00 ± 50.00
ND = not detectable; NP= not performed.
presentation of the disease, we observed a
tendency of IL-2 levels to decrease from group I
to group V, while IFN levels were randomly
distributed (H = NS for both IL-2 and IFN). 
Sixty-six patients did not have concomitant
pathologies or were considered to be clinically
compensated (-), whereas 25 not controlled were
classified as (+). Their serum cytokine levels are
presented in Table 2. There was no difference in
the IFN-γ (Z = 0.74; p = 0.22). However, serum
IL-2 levels were higher in the non-controlled
patients (Z = 3.895, p < 0.001).
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DISCUSSION
Like many other parasitic infections, T. cruzi
induces al terat ion in the immunological
system of the host to circumvent his defense
mechanisms10. IL-2, IFN-γ and TNF-α probably
contribute to the control of parasite growth by
tr iggering phagocytic cel l  act ivat ion and
inflammation1. There are also evidences that, in
addition to mechanical damage related to the
presence of the parasite, infection by T. cru z i
induces proinflammatory cytokine production
in the myocardium itself, which may further
exacerbate the pathology5 12.
Serum cytokine quantification has seldom
been reported in Chagas' disease. One major
reason for this is the widespread involvement of
cytokines in inflammatory responses that may
impair the interpretation of serum cytokine levels.
In the present investigation, we studied the
serum levels of IL-2, IFN-γ and TNF in different
clinical forms of Chagas' disease. The serum
cytokine levels in patients with the chronic form
of the disease did not differ from those of normal
individuals, suggesting a lack of activation of the
TH1 lymphocyte response. Since most of our
patients presented the cardiac form of the disease,
these results agree with recent experimental
studies suggesting that a lower level of TH1
activity may play a role in cardiac involvement,
whereas an enhanced TH-1-type response is
related to protective immunity and decreased
pathogenesis14 18. Serum TNF-α levels were
undetectable in both chronic chagasic patients
and normal individuals. Serum IFN-γ levels also
did not differ among clinical forms and the stage
of the disease. Variations have been reported
between symptomatic versus indeterminate form
and in patients with cardiac and indeterminate
form. However, cytokine profile does not seem
to differentiate the clinical presentations of the
disease. 
In contrast, serum IL-2 levels were significantly
increased in patients with decompensated cardiac
function. IL-2 is a glycoprotein of pleotropic eff e c t s
including the activation and proliferation of T
cells, natural killer cells and B cells. Suppression
of the IL-2 gene with deficient serum IL-2 and
IL-2 receptor expression, apparently mediated by
suppressor macrophages, is a well documented
phenomenon occurring during acute infection
which possibly plays an important role in the
evolution of the disease19 28. Nonetheless, its
role in Chagas' disease is still poorly understood.
It is intriguing to note that IL-2 levels increase
strikingly in non-compensated individuals, even
though their distribution pattern in the different
forms of the disease suggest an inverse
correlation with more aggressive forms of the
disease (Table 1).
It is frequently difficult to appraise the clinical
condition of Chagas' disease patients, because
of their misleading autonomic symptoms adjoined
by specific social and cultural characteristics.
Our results suggest that IL-2 may be related to
the severity of the disease. Its increased level in
non-compensated patients may be useful a
useful tool in the clinical evaluation of these
patients as an indicator of the need for more
aggressive or invasive procedures. 
Table 2 - Serum thyroid hormones and cytokines levels of 66 patients with Chagas' disease with a compensated clinical
picture (-) and of 25 non-compensated patients (+). Values are reported as mean ± SEM.
Clinical TSH T4l T3 T4 Tg IL-2 TNF IFN-γ
presentation mU/L ng/dL ng/dL µg/dL ng/dL pg/dL pg/dL pg/dL
(-) 5.32 ± 0.65 1.19 ± 0.14 123.44 ± 15.19 8.8 ± 1.0 54.09 ± 6.67 613.11 ± 75.46 ND 120.82 ± 14.87
(+) 5.37 ± 1.07 1.43 ± 0.28 110.66 ± 22.13 7.6 ± 1.5 27.98 ± 5.59 2506.18 ± 501.23 ND 134.91 ± 26.98
ND = not detectable.
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